Bio-Rad Laboratories Class A
BIO
Market cap $6.31B

231.70 USD

+4.79

2.11%

At close Jun 16, 4:00 PM EDT

After hours

231.70

+0.00

0.00%

1 day

2.11%

5 days

1.78%

1 month

-6.82%

3 months

-9.84%

6 months

-32.44%

Year to date

-28.96%

1 year

-21.66%

5 years

-49.08%

10 years

56.07%

About: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Employees: 7,700

Healthcare Medical Devices

0

Funds holding %

of 7,299 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

2.25% more ownership

Funds ownership: 81.88% [Q4 2024] → 84.13% (+2.25%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]

4% less call options, than puts

Call options by funds: $3.6M | Put options by funds: $3.77M

6% less funds holding

Funds holding: 445 [Q4 2024] → 420 (-25) [Q1 2025]

18% less repeat investments, than reductions

Existing positions increased: 132 | Existing positions reduced: 160

20% less first-time investments, than exits

New positions opened: 68 | Existing positions closed: 85

24% less capital invested

Capital invested by funds: $6.17B [Q4 2024] → $4.67B (-$1.49B) [Q1 2025]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$245

6%

upside

Avg. target

$324

40%

upside

High target

$392

69%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

Wells Fargo Brandon Couillard	6%upside $245	Equal-Weight Maintained	9 Jun 2025
UBS Dan Leonard	34%upside $310	Buy Maintained	2 May 2025
Citigroup Patrick Donnelly	51%upside $350	Buy Maintained	2 May 2025
RBC Capital Conor McNamara	69%upside $392	Outperform Maintained	2 May 2025

See Analyst Rankings

Financial journalist opinion

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Operating Officer Jon DiVincenzo will host one-on-one meetings with investors during the Jefferies Global Healthcare Conference in New York City, on June 4, 2025. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range o.

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

Zacks Investment Research

Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends

Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 PM Eastern Time (10:35 AM Pacific Time). A live webcast and subsequent replay of the.

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

Zacks Investment Research

BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket

Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.

BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket

Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2025 Earnings Conference Call May 1, 2025 5:30 PM ET Company Participants Edward Chung - Head of Investor Relations Jon DiVincenzo - President and Chief Operating Officer Roop Lakkaraju - Executive Vice President and Chief Financial Officer Norman Schwartz - Chief Executive Officer Conference Call Participants Patrick Donnelly - Citigroup Dan Leonard - UBS Brandon Couillard - Wells Fargo Conor McNamara - RBC Capital Markets Jack Meehan - Nephron Research Operator Ladies and gentlemen, thank you for standing by. My name is Desyree, and I will be your conference operator today.

Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $1.73 per share. This compares to earnings of $2.29 per share a year ago.

Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates

Bio-Rad Reports First-Quarter 2025 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: “We navigated a highly dynamic first quarter that became progressively more challenging, yet we delivered solid margins through focused execution and careful expense management. Given the.

Bio-Rad Reports First-Quarter 2025 Financial Results

Zacks Investment Research

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the market next year.

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

See News Rankings

Charts implemented using Lightweight Charts™